Lilly to stop development of lymphoma drug enzastaurin

05/12/2013 | Genetic Engineering & Biotechnology News

Eli Lilly & Co. said it would stop developing the experimental drug enzastaurin as a treatment for diffuse large B-cell lymphoma after obtaining unfavorable results from a late-stage trial. The drug failed to significantly improve disease-free survival against placebo in patients at high risk of relapse after chemotherapy.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY